Last Updated: November 19, 2026

EPIRUBICIN HYDROCHLORIDE - Generic Drug Details

« Back to Dashboard


What are the generic sources for epirubicin hydrochloride and what is the scope of freedom to operate?

Epirubicin hydrochloride is the generic ingredient in two branded drugs marketed by Pfizer Inc, Actavis Totowa, Cipla Ltd, Ebewe Pharma, Epic Pharma Llc, Fresenius Kabi Usa, Hikma, Hisun Pharm Hangzhou, Hospira, Impax Labs Inc, and Pharmobedient, and is included in fifteen NDAs. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for EPIRUBICIN HYDROCHLORIDE
US Patents:0
Tradenames:2
Applicants:11
NDAs:15
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 66
Clinical Trials: 503
Patent Applications: 7,626
What excipients (inactive ingredients) are in EPIRUBICIN HYDROCHLORIDE?EPIRUBICIN HYDROCHLORIDE excipients list
DailyMed Link:EPIRUBICIN HYDROCHLORIDE at DailyMed
Recent Clinical Trials for EPIRUBICIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Affiliated Hospital of Nantong UniversityPHASE2
Eye & ENT Hospital of Fudan UniversityPHASE2
First Affiliated Hospital of Wenzhou Medical UniversityPHASE2

See all EPIRUBICIN HYDROCHLORIDE clinical trials

Pharmacology for EPIRUBICIN HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for EPIRUBICIN HYDROCHLORIDE

US Patents and Regulatory Information for EPIRUBICIN HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira EPIRUBICIN HYDROCHLORIDE epirubicin hydrochloride INJECTABLE;INJECTION 065343-001 Apr 19, 2007 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Fresenius Kabi Usa EPIRUBICIN HYDROCHLORIDE epirubicin hydrochloride INJECTABLE;INJECTION 065408-002 Oct 15, 2007 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Actavis Totowa EPIRUBICIN HYDROCHLORIDE epirubicin hydrochloride INJECTABLE;INJECTION 065445-002 Sep 18, 2008 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma EPIRUBICIN HYDROCHLORIDE epirubicin hydrochloride INJECTABLE;INJECTION 065289-002 Jun 27, 2007 AP RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hospira EPIRUBICIN HYDROCHLORIDE epirubicin hydrochloride INJECTABLE;INJECTION 065343-004 Apr 19, 2007 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Epirubicin Hydrochloride Market Dynamics, Patent Status, Competition, and Financial Trajectory

Last updated: November 10, 2026

Epirubicin hydrochloride is an established generic anthracycline used mainly in breast cancer and selected bladder, gastric, lymphoma, sarcoma, and other oncology protocols. Its commercial profile is defined by low unit pricing, hospital procurement, generic competition, supply reliability, and clinical substitution rather than patent exclusivity. The originator product, Ellence, no longer has meaningful U.S. market protection, and no biosimilar pathway applies because epirubicin is a small-molecule drug. Public financial reporting does not disclose standalone epirubicin revenue.

What is epirubicin hydrochloride and how is it used?

Epirubicin hydrochloride is the hydrochloride salt of epirubicin, an anthracycline cytotoxic agent. It intercalates DNA and inhibits topoisomerase II, producing antitumor activity but also dose-limiting cardiotoxicity and myelosuppression.

The drug is administered intravenously. Its principal labeled U.S. indication is adjuvant therapy for patients with evidence of axillary-node tumor involvement after resection of primary breast cancer, usually as part of combination chemotherapy [1].

Outside the United States, epirubicin has broader historical use in:

  • Breast cancer
  • Non-muscle-invasive and muscle-invasive bladder cancer
  • Gastric cancer
  • Ovarian cancer
  • Lymphomas
  • Soft-tissue sarcoma
  • Other solid tumors under national or institutional protocols

Epirubicin is commonly compared with doxorubicin. It has a broadly similar anthracycline mechanism, while clinical use depends on cumulative dose, regimen design, toxicity profile, local guidelines, and formulary economics.

What is the FDA regulatory status of epirubicin hydrochloride?

The FDA approved Ellence, epirubicin hydrochloride injection, under NDA 050718 in 1999. Pharmacia & Upjohn was the original U.S. sponsor. The product is supplied as an intravenous injection in multiple strengths, including 50 mg/25 mL and 200 mg/100 mL presentations in commonly referenced labeling [1, 2].

The regulatory position is mature:

Regulatory item Status
Active ingredient Epirubicin hydrochloride
Dosage form Intravenous injection
Drug class Anthracycline antineoplastic
Original U.S. brand Ellence
Original U.S. approval 1999
U.S. approval holder historically associated with brand Pharmacia & Upjohn
Main U.S. indication Adjuvant therapy for node-positive breast cancer
Prescription status Prescription oncology drug
Biosimilar pathway Not applicable
Market structure Generic and institutional procurement driven

The U.S. label carries boxed warnings for cardiomyopathy, secondary malignancies, extravasation injury, severe myelosuppression, and other serious toxicities [1].

When did epirubicin lose exclusivity?

Epirubicin lost practical exclusivity years ago. The product is now a mature generic oncology medicine, and commercial access is determined primarily by abbreviated new drug applications, manufacturing capacity, hospital contracts, and national reimbursement systems.

FDA exclusivity periods associated with the original product have expired. Any historical patents linked to the innovator product are also beyond their enforceable commercial life for ordinary generic-entry purposes. The current market does not depend on an active composition-of-matter patent.

The key commercial distinction is between regulatory exclusivity and supply-chain access:

  • Regulatory exclusivity is no longer a material barrier.
  • Generic approval is available through the ANDA pathway.
  • Hospital and group-purchasing contracts can still affect market access.
  • Manufacturing interruptions can create temporary pricing power.
  • Product quality, sterile manufacturing capacity, and injectable supply reliability are more important than patent ownership.

What patents protect epirubicin hydrochloride?

No active, commercially meaningful U.S. patent estate is generally associated with the mature epirubicin hydrochloride market. The original product’s protection was based on historical anthracycline chemistry and product-related rights that have expired or ceased to constrain ordinary generic entry.

The relevant intellectual-property categories are:

Patent category Current commercial relevance
Active ingredient or composition patents No material barrier identified for standard epirubicin hydrochloride
Salt-form patents No material barrier for routine generic supply
Injectable formulation patents Potentially relevant only to a specific protected formulation, if any
Method-of-use patents Limited relevance where treatment protocols are established and generic labeling differs
Manufacturing-process patents May protect a supplier’s process but generally do not block all generic production
Drug-delivery patents Relevant only to specialized liposomal, nanoparticle, or combination products

A supplier can maintain confidential know-how covering impurity control, crystallization, sterilization, vial filling, stability, and scale-up. Those trade secrets can create operational advantages without creating broad market exclusivity.

What is the Orange Book status of epirubicin hydrochloride?

The Orange Book is relevant to the U.S. reference product, Ellence, and any approved generic products with therapeutic-equivalence determinations. Because the product is old and genericized, the Orange Book is not expected to show an unexpired patent listing that materially delays entry for standard epirubicin hydrochloride injection.

The commercial implications are:

  1. Generic applicants do not face a current composition patent barrier.
  2. Paragraph IV litigation is not a central market event.
  3. A later entrant would usually compete on approval status, price, supply, and contracting.
  4. Any patent dispute would more likely concern a specialized formulation, manufacturing method, or delivery technology than conventional epirubicin injection.

The Orange Book’s TE code and applicant listings remain relevant for procurement decisions, but therapeutic equivalence does not guarantee identical vial sizes, preservatives, packaging, or institutional handling characteristics.

Are there Paragraph IV challenges involving epirubicin?

Paragraph IV challenges are not a meaningful current driver for standard epirubicin hydrochloride. Paragraph IV certifications are most commercially significant when an ANDA applicant challenges listed, unexpired patents. Epirubicin’s conventional injectable market is too mature for ordinary patent litigation to define entry timing.

The more relevant entry routes are:

  • Paragraph III certification against expired patents
  • No-patent certification
  • ANDA approval based on a mature reference product
  • Market entry after manufacturing and inspection readiness
  • Product launch following supply-contract awards

A generic applicant can still face regulatory delay from deficiencies, facility inspections, stability data, extractables and leachables, or sterile manufacturing controls. Those issues are operational rather than patent-based.

What formulations are protected by epirubicin patents?

The commercially established formulation is an aqueous intravenous epirubicin hydrochloride injection. Its value is concentrated in sterile manufacturing, concentration control, vial presentation, storage stability, and safe handling.

Specialized formulations may create separate intellectual-property opportunities:

Liposomal epirubicin

Liposomal delivery can seek to alter tissue distribution, tolerability, or pharmacokinetics. A liposomal product would likely require separate clinical and regulatory support rather than relying on a conventional injectable generic pathway.

Nanoparticle or targeted formulations

Nanoparticle systems, antibody-linked delivery, and tumor-targeted formulations could generate new patent claims covering composition, particle size, targeting ligands, release profiles, or treatment methods. These products would compete in a different value segment from standard epirubicin.

Combination products

Patents may cover fixed or co-formulated combinations with other oncology agents. Combination claims face technical and regulatory hurdles because clinical benefit, compatibility, dosing, and manufacturing consistency must be demonstrated.

No specialized epirubicin formulation has displaced the conventional injection as the primary commercial product in the mature generic market.

Which companies compete in the epirubicin hydrochloride market?

Competition is fragmented and varies by country. Manufacturers and suppliers can include multinational generic companies, specialty injectable manufacturers, regional oncology suppliers, and contract manufacturers. The exact supplier roster changes because hospital tenders, discontinuations, shortages, and licensing arrangements alter national availability.

The competitive set includes:

  • Generic injectable oncology manufacturers
  • Hospital-focused sterile injectables companies
  • Regional suppliers in Europe, Asia, and Latin America
  • Contract development and manufacturing organizations
  • Distributors purchasing through public and private tenders

Epirubicin also competes therapeutically with:

  • Doxorubicin
  • Liposomal doxorubicin
  • Mitoxantrone in selected settings
  • Taxane-based combinations
  • Cyclophosphamide-containing regimens
  • Targeted breast cancer therapies
  • Immunotherapies and antibody-drug conjugates in eligible patients

The strongest competitive pressure comes from treatment substitution. In breast cancer, anthracycline use has declined in some segments as clinicians adopt risk-adapted regimens, genomic testing, HER2-directed therapy, taxanes, and other targeted agents.

How does epirubicin compare with doxorubicin?

Factor Epirubicin Doxorubicin
Drug class Anthracycline Anthracycline
Administration Intravenous Intravenous
U.S. brand history Ellence Adriamycin
Generic availability Broad and mature Broad and mature
Main commercial use Breast cancer and international oncology protocols Broad solid-tumor and hematologic use
Cardiotoxicity concern Material Material
Patent-driven pricing No meaningful current protection No meaningful current protection
Competitive position Protocol and formulary dependent More widely embedded in global protocols
Main differentiation Regimen selection and clinical familiarity Breadth of indications and long clinical history

Epirubicin has historically been used where clinicians seek an anthracycline option with a different dose-intensity or toxicity profile. The distinction does not create substantial pricing power in a generic hospital market.

What is the financial trajectory of epirubicin hydrochloride?

Epirubicin’s financial trajectory is mature-to-declining in value terms, with intermittent volume resilience. Public companies generally do not report epirubicin revenue separately because sales are aggregated into oncology, hospital injectables, or established pharmaceutical portfolios.

The likely revenue pattern is:

Period Financial profile
Original launch period Premium branded oncology pricing
Generic-entry period Rapid price erosion and supplier expansion
Mature generic period Low unit pricing, tender-driven revenue
Current market Stable clinical demand with limited pricing power
Supply disruption periods Temporary price increases or allocation gains
Long-term outlook Volume retention in selected protocols, value pressure from substitution

Revenue exposure is more meaningful for manufacturers with a large sterile-injectable portfolio than for companies with a single epirubicin product. A supplier may benefit from:

  • Multi-year hospital tenders
  • National reimbursement inclusion
  • Scarcity of qualified sterile-injectable capacity
  • Portfolio bundling with other oncology medicines
  • Geographic markets with limited local competition

The main financial risks are generic price compression, tender losses, raw-material shortages, manufacturing observations, product recalls, and declining anthracycline use in selected breast cancer populations.

What patent litigation affects epirubicin?

No major ongoing U.S. patent litigation is central to the conventional epirubicin hydrochloride injection market. Litigation risk is low relative to newer oncology drugs because:

  • The active ingredient is long established.
  • Generic entry has already occurred.
  • There is no apparent blocking composition patent.
  • The product is not a biologic.
  • Market pricing limits the economic incentive for extensive litigation.

Potential disputes could still arise over:

  • ANDA product quality
  • Trade dress and packaging
  • Manufacturing processes
  • Contract rights
  • Supply agreements
  • Specialized delivery technologies
  • False advertising or therapeutic-equivalence claims

These disputes would generally have limited effect on the broad market unless they involved a major supplier or a product shortage.

What generic launch scenarios exist for epirubicin?

A conventional generic launch does not require a major patent settlement. The principal scenarios are:

Low-price tender launch

A new supplier enters through a national or hospital tender and wins volume with aggressive pricing. This can reduce incumbent share quickly but may compress margins across the category.

Supply-constrained launch

A supplier enters when incumbent manufacturers face shortages, plant closures, or regulatory restrictions. Market share can expand rapidly, although the entrant must maintain reliable sterile production.

Regional launch

A company receives approval in one jurisdiction but remains commercially limited by local reimbursement, distributor access, or tender timing.

Portfolio launch

Epirubicin is introduced alongside doxorubicin, oxaliplatin, paclitaxel, or other oncology injectables. The supplier uses portfolio breadth to secure institutional contracts.

Specialized formulation launch

A liposomal or targeted epirubicin product would face greater development cost, clinical differentiation requirements, and potentially new patent protection. This would not be a conventional generic launch.

What manufacturing and geographic barriers affect epirubicin?

The principal barriers are manufacturing and procurement related. Sterile oncology production requires validated aseptic processing, containment systems, operator protection, environmental controls, and reliable quality systems.

Geographic market conditions differ:

Region Market characteristics
United States Mature generic market, hospital purchasing, FDA quality oversight
European Union National reimbursement and hospital tenders, multiple suppliers
China Large oncology demand, domestic manufacturing and centralized procurement influence
India Strong generic manufacturing base and export orientation
Latin America Country-specific registration, public procurement, distributor dependence
Middle East and Africa Import reliance and supply continuity are important

Epirubicin is hazardous to handle, which raises operational requirements for production, pharmacy preparation, and waste disposal. Those requirements can reduce the number of qualified suppliers even when patents no longer limit entry.

Is epirubicin exposed to biosimilar competition?

No. Epirubicin hydrochloride is a chemically synthesized small molecule, not a biologic. Biosimilar approval standards therefore do not apply.

Its competitive risk comes from:

  • Other generic anthracyclines
  • Liposomal doxorubicin
  • Non-anthracycline chemotherapy
  • Targeted breast cancer agents
  • Antibody-drug conjugates
  • Immunotherapy
  • Treatment de-escalation in lower-risk disease

The absence of biosimilar risk does not eliminate competitive pressure. Therapeutic substitution is more important than biosimilar entry.

How strong is the epirubicin patent estate?

The patent estate is weak from a market-exclusivity perspective and strong only in the limited sense that the drug has an established regulatory and manufacturing history.

Dimension Assessment
Composition-of-matter protection Expired or commercially irrelevant
Regulatory exclusivity Expired
Formulation protection Limited for conventional injection
Method-of-use protection Limited in mature labeled indications
Manufacturing know-how Potentially valuable to individual suppliers
Litigation exposure Low
Generic-entry risk High
Pricing power Low
Supply-chain value Moderate during shortages
Long-term commercial moat Narrow

Key Takeaways

  • Epirubicin hydrochloride is a mature generic anthracycline with no meaningful current patent barrier in conventional intravenous injection.
  • Ellence, the original U.S. brand, was approved in 1999 and no longer has practical exclusivity.
  • The Orange Book is relevant for reference-product and generic status, but Paragraph IV litigation is not a central market issue.
  • No biosimilar pathway applies because epirubicin is a small molecule.
  • Financial performance is driven by hospital tenders, sterile manufacturing capacity, supply continuity, and therapeutic substitution.
  • Public companies generally do not disclose standalone epirubicin revenue.
  • The commercial outlook is stable in established oncology protocols but pressured by generic price erosion and newer breast cancer therapies.
  • Specialized liposomal, nanoparticle, or combination formulations could create new intellectual-property value, but conventional epirubicin injection has limited patent strength.
  • The main generic-entry risks are manufacturing quality, facility capacity, regulatory approval, and contract access rather than patent litigation.

FAQs

Is epirubicin hydrochloride still commercially available?

Yes. It remains available through generic oncology suppliers in multiple markets, although product availability can vary by country, tender cycle, manufacturer, and sterile-injectable supply conditions.

Does epirubicin hydrochloride have an active U.S. composition patent?

No commercially meaningful active composition patent is generally associated with conventional epirubicin hydrochloride injection.

Can a company launch generic epirubicin without settling patent litigation?

Yes. The mature product generally does not require a patent settlement for standard generic entry because the principal historical exclusivity barriers have expired.

Is epirubicin more profitable than doxorubicin?

Usually not on a unit basis. Both are mature generic anthracyclines, and profitability depends more on manufacturing cost, tender pricing, shortage conditions, and portfolio contracting than on the molecule alone.

What is the largest long-term threat to epirubicin demand?

Therapeutic substitution is the largest structural threat. Targeted breast cancer drugs, antibody-drug conjugates, immunotherapies, taxanes, and risk-adapted treatment protocols can reduce anthracycline use in selected patients.

References

  1. U.S. Food and Drug Administration. (2010). Ellence (epirubicin hydrochloride) injection prescribing information. FDA.

  2. DailyMed. (2024). Epirubicin hydrochloride injection. National Library of Medicine.

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

  4. National Cancer Institute. (2024). Epirubicin hydrochloride. NCI Drug Dictionary.

  5. European Medicines Agency. (2024). Epirubicin-containing medicinal products and product information. EMA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.